Quantitative mechanistic model reveals key determinants of placental IgG transfer and informs prenatal immunization strategies
PLOS Computational Biology · 07.11.2023 · 19 (11) · e1011109
DOI: 10.1371/journal.pcbi.1011109 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, online erschienen am 07.11.2023. Verfasst von Remziye E Wessel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Virginia School of Medicine, Charlottesville, Virginia, United States of America. Hauptthemen laut MEDLINE: Vaccines, Whooping Cough. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Thomas F. and Kate Miller Jeffress Memorial Trust and Bank of America, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Transplacental antibody transfer is crucially important in shaping neonatal immunity. Recently, prenatal maternal immunization has been employed to boost pathogen-specific immunoglobulin G (IgG) transfer to the fetus. Multiple factors have been implicated in antibody transfer, but how these key regulators work together to elicit selective transfer is pertinent to engineering vaccines for mothers to optimally immunize their newborns. Here, we present the first quantitative mechanistic model to uncover the determinants of placental antibody transfer and inform personalized immunization approaches. We identified placental FcγRIIb expressed by endothelial cells as a limiting factor in receptor-mediated transfer, which plays a key role in promoting preferential transport of subclasses IgG1, IgG3, and IgG4, but not IgG2. Integrated computational modeling and in vitro experiments reveal that IgG subclass abundance, Fc receptor (FcR) binding affinity, and FcR abundance in syncytiotrophoblasts and endothelial cells contribute to inter-subclass competition and potentially inter- and intra-patient antibody transfer heterogeneity. We developed an in silico prenatal vaccine testbed by combining a computational model of maternal vaccination with this placental transfer model using the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine as a case study. Model simulations unveiled precision prenatal immunization opportunities that account for a patient’s anticipated gestational length, placental size, and FcR expression by modulating vaccine timing, dosage, and adjuvant. This computational approach provides new perspectives on the dynamics of maternal-fetal antibody transfer in humans and potential avenues to optimize prenatal vaccinations that promote neonatal immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Virginia School of Medicine, Charlottesville, Virginia, United States of America.
- Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, Virginia, United States of America.
ORCID-Profile: Sepideh Dolatshahi
Förderung
- NIGMS NIH HHS
- Thomas F. and Kate Miller Jeffress Memorial Trust and Bank of America
- National Institute of General Medical Sciences
Zitieren
APA
Wessel, R. E., & Dolatshahi, S. (2023). Quantitative mechanistic model reveals key determinants of placental IgG transfer and informs prenatal immunization strategies. PLOS Computational Biology, 19(11), e1011109. https://doi.org/10.1371/journal.pcbi.1011109
Vancouver
Wessel RE, Dolatshahi S. Quantitative mechanistic model reveals key determinants of placental IgG transfer and informs prenatal immunization strategies. PLOS Computational Biology. 2023;19(11):e1011109. doi:10.1371/journal.pcbi.1011109
BibTeX
@article{Wessel2023,
author = {Wessel, Remziye E and Dolatshahi, Sepideh},
title = {Quantitative mechanistic model reveals key determinants of placental IgG transfer and informs prenatal immunization strategies},
journal = {PLOS Computational Biology},
year = {2023},
volume = {19},
number = {11},
pages = {e1011109},
doi = {10.1371/journal.pcbi.1011109}
}
EUVIMED